PLoS ONE · 2014 · 28 citations · 36 references
Life SciencesImmunologyPharmacologyImmunoregulationMolecular OncologySignal TransductionAntitumor T Cell ResponsesCancer ImmunotherapyEnzyme InhibitionPharmacodynamics Of ImmunotherapiesT Cell Responses To TumorsCancer-associated ImmunosuppressionHost Immune RejectionImmunosuppressive CompoundsIndoleamine 2, 3-Dioxygenase PathwayPost-transcriptional RegulationProteasome Inhibitor TherapyTumor ImmunosurveillanceTumor-associated Enzyme Targeting
Indoleamine 2,3-dioxygenase (IDO) is found in multiple malignancies and exerts immunosuppressive effects that are central in protecting tumors from host T lymphocyte rejection. IDO is an enzyme involved in the catabolism of tryptophan resulting in inhibition of T lymphocyte function. While inhibition of IDO enzymatic activity results in tumor rejection, it is still unknown how we can directly target IDO expression within tumors using drugs. We have chosen to interfere with IDO expression by targeting the key-signaling event signal transducer and activator of transcription 1 (STAT1). We evaluated the efficacy of fludarabine, previously described to inhibit STAT1 phosphorylation. Interestingly, fludarabine was efficient in suppressing protein expression and consequently IDO activity in two different cell lines derived from breast cancer and melanoma when IDO was activated with interferon-gamma (IFN-γ) or supernatants prepared from activated T lymphocytes. However, fludarabine had no inhibitory effect on STAT1 phosphorylation. Other IFN-γ-responsive genes were only marginally inhibited by fludarabine. The level of IDO transcript was unaffected by this inhibitor, suggesting the involvement of post-transcriptional control. Strikingly, we have found that the inhibition of proteasome partially protected IDO from fludarabine-induced degradation, indicating that fludarabine induces IDO degradation through a proteasome-dependent pathway. Currently used in the clinic to treat some malignancies, fludarabine has the potential for use in the treatment of human tumors through induction of IDO degradation and consequently, for the promotion of T cell-mediated anti-tumor response.
36
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
David H. Munn, Min Zhou, John T. Attwood et al. · Science · 1998 · 2.6K citations
Mark E. Dudley, John R. Wunderlich, James Chih‐Hsin Yang et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text
Medicine, Immunology, Oncology +17